|
WO2020254179A1
|
|
Pharmaceutical compositions in the form of gel containing xyloglucan and alcohols for the controlled release of active ingredients
|
|
WO2019180199A1
|
|
Stable aqueous composition of phosphocreatine
|
|
US2019314402A1
|
|
Oral compositions for the treatment of gastroesophageal reflux
|
|
EP3381474A1
|
|
Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy
|
|
ITUB20152376A1
|
|
LACTOBACILLUS PARACASEI FOR THE PRODUCTION OF CONJUGATED LINOLEIC ACID, NUTRITIONAL AND PHARMACEUTICAL PREPARATIONS THAT INCLUDE IT AND THEIR USE
|
|
EP3143027A1
|
|
New solvated crystal form of rifaximin, production, compositions and uses thereof
|
|
AU2014359649A1
|
|
Composition useful for promoting female fertility
|
|
EP3009013A1
|
|
Therapeutic and nutritional compositions for the treatment of irritable bowel syndrome
|
|
EP2952209A1
|
|
Homogeneous formulations comprising omega-3 polyunsaturated fatty acids (n-3 PUFA) and resveratrol for oral administration
|
|
EP2870163A1
|
|
Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof
|
|
EP2780467A2
|
|
Assays and methods for selecting a treatment regimen for a subject with depression and methods for treatment
|
|
EP2582368A1
|
|
Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue
|
|
AU2004231377A1
|
|
A medicament for the two-step perioperative therapy of solid tumours
|
|
AU2003224443A1
|
|
Combined use of L-carnitine, acetyl L-carnitine and propionyl L-carnitine for the treatment of oligoasthenoteratospermia
|
|
AU2003215900A1
|
|
Anti-human tenascin monoclonal antibody
|
